> Details

Johannesen, Katrine M.; Gardella, Elena; Linnankivi, Tarja; Courage, Carolina; de Saint Martin, Anne; Lehesjoki, Anna‐Elina; Mignot, Cyril; Afenjar, Alexandra; Lesca, Gaetan; Abi‐Warde, Marie‐Thérèse; Chelly, Jamel; Piton, Amélie; Merritt, J. Lawrence; Rodan, Lance H.; Tan, Wen‐Hann; Bird, Lynne M.; Nespeca, Mark; Gleeson, Joseph G.; Yoo, Yongjin; Choi, Murim; Chae, Jong‐Hee; Czapansky‐Beilman, Desiree; Reichert, Sara Chadwick; Pendziwiat, Manuela; [...]

Defining the phenotypic spectrum of SLC6A1 mutations

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Defining the phenotypic spectrum of SLC6A1 mutations
  • Contributor: Johannesen, Katrine M.; Gardella, Elena; Linnankivi, Tarja; Courage, Carolina; de Saint Martin, Anne; Lehesjoki, Anna‐Elina; Mignot, Cyril; Afenjar, Alexandra; Lesca, Gaetan; Abi‐Warde, Marie‐Thérèse; Chelly, Jamel; Piton, Amélie; Merritt, J. Lawrence; Rodan, Lance H.; Tan, Wen‐Hann; Bird, Lynne M.; Nespeca, Mark; Gleeson, Joseph G.; Yoo, Yongjin; Choi, Murim; Chae, Jong‐Hee; Czapansky‐Beilman, Desiree; Reichert, Sara Chadwick; Pendziwiat, Manuela; [...]
  • imprint: Wiley, 2018
  • Published in: Epilepsia
  • Language: English
  • DOI: 10.1111/epi.13986
  • ISSN: 0013-9580; 1528-1167
  • Origination:
  • Footnote:
  • Description: <jats:title>Summary</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Pathogenic <jats:italic>SLC6A1</jats:italic> variants were recently described in patients with myoclonic atonic epilepsy (MAE) and intellectual disability (ID). We set out to define the phenotypic spectrum in a larger cohort of <jats:italic>SCL6A1</jats:italic>‐mutated patients.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We collected 24 <jats:italic>SLC6A1</jats:italic> probands and 6 affected family members. Four previously published cases were included for further electroclinical description. In total, we reviewed the electroclinical data of 34 subjects.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Cognitive development was impaired in 33/34 (97%) subjects; 28/34 had mild to moderate ID, with language impairment being the most common feature. Epilepsy was diagnosed in 31/34 cases with mean onset at 3.7 years. Cognitive assessment before epilepsy onset was available in 24/31 subjects and was normal in 25% (6/24), and consistent with mild ID in 46% (11/24) or moderate ID in 17% (4/24). Two patients had speech delay only, and 1 had severe ID. After epilepsy onset, cognition deteriorated in 46% (11/24) of cases. The most common seizure types were absence, myoclonic, and atonic seizures. Sixteen cases fulfilled the diagnostic criteria for MAE. Seven further patients had different forms of generalized epilepsy and 2 had focal epilepsy. Twenty of 31 patients became seizure‐free, with valproic acid being the most effective drug. There was no clear‐cut correlation between seizure control and cognitive outcome. Electroencephalography (EEG) findings were available in 27/31 patients showing irregular bursts of diffuse 2.5‐3.5 Hz spikes/polyspikes‐and‐slow waves in 25/31. Two patients developed an EEG pattern resembling electrical status epilepticus during sleep. Ataxia was observed in 7/34 cases. We describe 7 truncating and 18 missense variants, including 4 recurrent variants (Gly232Val, Ala288Val, Val342Met, and Gly362Arg).</jats:p></jats:sec><jats:sec><jats:title>Significance</jats:title><jats:p>Most patients carrying pathogenic <jats:italic>SLC6A1</jats:italic> variants have an MAE phenotype with language delay and mild/moderate ID before epilepsy onset. However, ID alone or associated with focal epilepsy can also be observed.</jats:p></jats:sec>
  • Access State: Open Access